Meriofert Set (Follicle-Stimulating Hormone, Luteinising Hormone)

The two hormones bind to specific receptors on ovarian cells. FSH promotes the growth and maturation of ovarian follicles and stimulates estrogen production, while LH triggers the final maturation and ovulation of the dominant follicle, together supporting the development of multiple eggs for fertility treatment.

The dose of Meriofert Set is individualized. A qualified prescriber determines the amount and frequency based on the patient’s ovarian response, treatment protocol and clinical goals. No standard dosing regimen is provided in public information.

Meriofert Set is intended for use before conception to induce ovulation or stimulate the ovaries. It is not administered during an established pregnancy, and safety data for use while breastfeeding are limited. Treatment decisions should be made by a specialist in reproductive medicine.

To request Meriofert Set, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

Meriofert Set combines both FSH and LH in a single injectable formulation, which can simplify dosing compared with regimens that require separate FSH and LH preparations. Clinicians may choose it for protocols that benefit from simultaneous LH activity, while other products may offer only FSH or different dosing options.

Meriofert Set should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Meriofert Set is given by subcutaneous injection, typically into the abdominal wall or thigh. The injection is performed by a trained healthcare professional or a patient who has been instructed on proper aseptic technique and dosing.

The most serious risks include ovarian hyperstimulation syndrome, which can cause severe abdominal pain, fluid accumulation and electrolyte imbalance, and the possibility of multiple pregnancy. Rarely, allergic reactions such as anaphylaxis may occur. Patients should be monitored closely for these events.

Meriofert Set is contraindicated in individuals with known hypersensitivity to its components, active ovarian cysts, uncontrolled thyroid disease, or a history of severe ovarian hyperstimulation syndrome. It should also be avoided in patients for whom pregnancy is not desired during the treatment cycle.